These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36655608)

  • 41. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
    Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
    Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia.
    Zhu J; Wu Q; Wang J; Niu T
    Expert Rev Hematol; 2022 Apr; 15(4):375-382. PubMed ID: 35437111
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A 5-day outpatient regimen of azacitidine is effective and well tolerated in patients with acute myeloid leukemia unsuitable for intensive chemotherapy.
    O'Reilly MA; McHale C; Almazmi A; Hameed A; Benjamin D; O'Connell N; Murphy P; Quinn J; Thornton P; O'Gorman P; Frankova H; Sargent J; Verburgh E; McHugh J; Evans P; Enright H
    Leuk Lymphoma; 2014 Dec; 55(12):2950-1. PubMed ID: 24628297
    [No Abstract]   [Full Text] [Related]  

  • 44. Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study.
    Gemuenden C; Benz R; Senn O; Goede JS; Manz MG; Gerber B
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):811-5. PubMed ID: 26437871
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia].
    Huang YQ; Zhang XY; Wu SX; Guo XZ; Pan JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1641-1646. PubMed ID: 29262890
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
    Boumber Y; Kantarjian H; Jorgensen J; Wen S; Faderl S; Castoro R; Autry J; Garcia-Manero G; Borthakur G; Jabbour E; Estrov Z; Cortes J; Issa JP; Ravandi F
    Leukemia; 2012 Nov; 26(11):2428-31. PubMed ID: 22665218
    [No Abstract]   [Full Text] [Related]  

  • 48. Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.
    Keating GM
    Drugs; 2009; 69(17):2501-18. PubMed ID: 19911860
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.
    Krug U; Koschmieder A; Schwammbach D; Gerss J; Tidow N; Steffen B; Bug G; Brandts CH; Schaich M; Röllig C; Thiede C; Noppeney R; Stelljes M; Büchner T; Koschmieder S; Dührsen U; Serve H; Ehninger G; Berdel WE; Müller-Tidow C
    PLoS One; 2012; 7(12):e52695. PubMed ID: 23300745
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
    Ferrara F
    Hematol Oncol; 2014 Mar; 32(1):1-9. PubMed ID: 23512815
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia.
    Tamura A; Ishida T; Saito A; Yamamoto N; Yokoi T; Uemura S; Nino N; Fujiwara T; Tahara T; Nakamura S; Kozaki A; Kishimoto K; Hasegawa D; Kosaka Y
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27284. PubMed ID: 29893458
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
    Ramos F; Thépot S; Pleyer L; Maurillo L; Itzykson R; Bargay J; Stauder R; Venditti A; Seegers V; Martínez-Robles V; Burgstaller S; Récher C; Debén G; Gaidano G; Gardin C; Musto P; Greil R; Sánchez-Guijo F; Fenaux P;
    Leuk Res; 2015 Mar; 39(3):296-306. PubMed ID: 25601157
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
    Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
    Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
    [No Abstract]   [Full Text] [Related]  

  • 54. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
    Ravandi F; Issa JP; Garcia-Manero G; O'Brien S; Pierce S; Shan J; Borthakur G; Verstovsek S; Faderl S; Cortes J; Kantarjian H
    Cancer; 2009 Dec; 115(24):5746-51. PubMed ID: 19795507
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Azacitidine treatment for acute myeloid leukemia with myelodysplasia-related changes during peritoneal dialysis].
    Omatsu T; Udaka K; Shibata H; Sekimoto E; Ozaki S
    Rinsho Ketsueki; 2017; 58(12):2369-2374. PubMed ID: 29332868
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful Treatment of Behçet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation.
    Nakamura Y; Matsuguma M; Tokunaga Y; Yamamoto K; Tanaka M; Tanaka Y; Yujiri T; Tanizawa Y
    Intern Med; 2017; 56(10):1199-1202. PubMed ID: 28502936
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
    Scott LJ
    Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
    Falantes JF; Calderón C; Márquez-Malaver FJ; Aguilar-Guisado M; Martín-Peña A; Martino ML; Montero I; González J; Parody R; Pérez-Simón JA; Espigado I
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):80-6. PubMed ID: 24220615
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).
    Falantes J; Pleyer L; Thépot S; Almeida AM; Maurillo L; Martínez-Robles V; Stauder R; Itzykson R; Pinto R; Venditti A; Bargay J; Burgstaller S; Martínez MP; Seegers V; Cortesão E; Foncillas MÁ; Gardin C; Montesinos P; Musto P; Fenaux P; Greil R; Sanz MA; Ramos F;
    Leuk Lymphoma; 2018 May; 59(5):1113-1120. PubMed ID: 28838276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy.
    Kara A; Akın Belli A; Karakuş V; Dere Y; Kurtoğlu E
    Turk J Haematol; 2017 Jun; 34(2):192-193. PubMed ID: 28183685
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.